CT55

Across TCGA pan-cancer cohorts, CT55 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CT55 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CT55 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CT55 expression acts as an unfavorable survival marker.

OV and LIHC are the cancer types where CT55 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.289	0.692	.020	18	view →
LIHC	DFS	Median	All	0.046	0.553	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CT55–OV (OS)

Open the OV breakdown →